PMID- 37950317
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231122
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 15
IP  - 1
DP  - 2023 Nov 10
TI  - Impact of insulin resistance on mild cognitive impairment in type 2 diabetes 
      mellitus patients with non-alcoholic fatty liver disease.
PG  - 229
LID - 10.1186/s13098-023-01211-w [doi]
LID - 229
AB  - AIMS: Insulin resistance (IR) is a pivotal factor in the pathogenesis of type 2 
      diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). 
      Nevertheless, the impact of IR on cognitive dysfunction in T2DM patients with 
      NAFLD remains inadequately understood. We aim to investigate the effect of IR on 
      mild cognitive impairment (MCI) in T2DM individuals with NAFLD. MATERIALS AND 
      METHODS: 143 T2DM individuals were categorized into Non-MCI and MCI groups, as 
      well as Non-NAFLD and NAFLD groups. Clinical parameters and cognitive preference 
      test outcomes were compared. Correlation and regression analyses were executed to 
      explore the interconnections between IR and cognitive details across all T2DM 
      patients, as well as within the subgroup of individuals with NAFLD. RESULTS: In 
      comparison to the Non-MCI group, the MCI group displayed elevated HOMA-IR levels. 
      Similarly, the NAFLD group exhibited higher HOMA-IR levels compared to the 
      Non-NAFLD group. Additionally, a higher prevalence of MCI was observed in the 
      NAFLD group as opposed to the Non-NAFLD group. Notably, HOMA-IR levels were 
      correlated with Verbal Fluency Test (VFT) and Trail Making Test-B (TMTB) scores, 
      both related to executive functions. Elevated HOMA-IR emerged as a risk factor 
      for MCI in the all patients. Intriguingly, increased HOMA-IR not only correlated 
      with TMTB scores but also demonstrated an influence on TMTA scores, reflecting 
      information processing speed function in patients with NAFLD. CONCLUSION: IR 
      emerges as a contributory factor to cognitive dysfunction in T2DM patients. 
      Furthermore, it appears to underlie impaired executive function and information 
      processing speed function in T2DM individuals with NAFLD.
CI  - (c) 2023. The Author(s).
FAU - Zhang, Hui
AU  - Zhang H
AD  - Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The 
      First Affiliated Hospital, and College of Clinical Medicine of Henan University 
      of Science and Technology,, Luoyang, China.
FAU - Fareeduddin Mohammed Farooqui, Huzaifa
AU  - Fareeduddin Mohammed Farooqui H
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
FAU - Zhu, Wenwen
AU  - Zhu W
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
FAU - Niu, Tong
AU  - Niu T
AD  - Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
FAU - Zhang, Zhen
AU  - Zhang Z
AD  - Department of Endocrinology, Centre for Leading Medicine and Advanced 
      Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei, 
      China.
FAU - Zhang, Haoqiang
AU  - Zhang H
AD  - Department of Endocrinology, Centre for Leading Medicine and Advanced 
      Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life 
      Sciences and Medicine, University of Science and Technology of China, Hefei, 
      China. drhqzhang@ustc.edu.cn.
LA  - eng
GR  - RC2021178/Scientific Research Start-up Funds of The First Affiliated Hospital of 
      USTC/
GR  - 2023IHM02006/Research Funds of Center for Leading Medicine and Advanced 
      Technologies of IHM/
PT  - Journal Article
DEP - 20231110
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC10636824
OTO - NOTNLM
OT  - Mild cognitive impairment
OT  - Non-alcoholic fatty Liver Disease
OT  - Type 2 Diabetes Mellitus
COIS- The authors declare no competing interests.
EDAT- 2023/11/11 11:46
MHDA- 2023/11/11 11:47
PMCR- 2023/11/10
CRDT- 2023/11/11 00:08
PHST- 2023/09/20 00:00 [received]
PHST- 2023/11/03 00:00 [accepted]
PHST- 2023/11/11 11:47 [medline]
PHST- 2023/11/11 11:46 [pubmed]
PHST- 2023/11/11 00:08 [entrez]
PHST- 2023/11/10 00:00 [pmc-release]
AID - 10.1186/s13098-023-01211-w [pii]
AID - 1211 [pii]
AID - 10.1186/s13098-023-01211-w [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2023 Nov 10;15(1):229. doi: 10.1186/s13098-023-01211-w.